Standal T - Search Results

1

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N. Andersen NF, et al. Among authors: standal t. Br J Haematol. 2005 Jan;128(2):210-7. doi: 10.1111/j.1365-2141.2004.05299.x. Br J Haematol. 2005. PMID: 15638855 Free article.

2

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A. Standal T, et al. Blood. 2002 Oct 15;100(8):3002-7. doi: 10.1182/blood-2002-04-1190. Blood. 2002. PMID: 12351414 Free article.

3

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.

Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C. Standal T, et al. Blood. 2002 Dec 1;100(12):3925-9. doi: 10.1182/blood-2002-05-1406. Epub 2002 Jul 18. Blood. 2002. PMID: 12393395 Free article.

4

Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.

Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Børset M, Waage A; Nordic Myeloma Study Group. Seidel C, et al. Among authors: standal t. Br J Haematol. 2002 Dec;119(3):672-6. doi: 10.1046/j.1365-2141.2002.03898.x. Br J Haematol. 2002. PMID: 12437643 Free article. Clinical Trial.

5

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Børset M, Sundan A, Hjertner O. Standal T, et al. Haematologica. 2004 Feb;89(2):174-82. Haematologica. 2004. PMID: 15003892

6

Role of osteopontin in adhesion, migration, cell survival and bone remodeling.

Standal T, Borset M, Sundan A. Standal T, et al. Exp Oncol. 2004 Sep;26(3):179-84. Exp Oncol. 2004. PMID: 15494684

7

Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A. Hjertner Ø, et al. Among authors: standal t. Curr Drug Targets. 2005 Sep;6(6):701-11. doi: 10.2174/1389450054863716. Curr Drug Targets. 2005. PMID: 16178802 Review.

8

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A. Standal T, et al. Blood. 2007 Apr 1;109(7):3024-30. doi: 10.1182/blood-2006-07-034884. Blood. 2007. PMID: 17138824 Free article.

9

Bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A. Hjertner Ø, et al. Among authors: standal t. Med Oncol. 2006;23(4):431-41. doi: 10.1385/mo:23:4:431. Med Oncol. 2006. PMID: 17303901 Review.

10

High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.

Mylin AK, Abildgaard N, Johansen JS, Andersen NF, Heickendorff L, Standal T, Gimsing P, Knudsen LM. Mylin AK, et al. Among authors: standal t. Eur J Haematol. 2008 Apr;80(4):310-7. doi: 10.1111/j.1600-0609.2007.01027.x. Epub 2007 Dec 21. Eur J Haematol. 2008. PMID: 18182077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters